At its April 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) gave ...

"Oczyesa has the potential to advance the standard of care for patients living with acromegaly by enhancing octreotide plasma exposure and enabling easy and convenient once-monthly self ...

It is intended for patients with acromegaly who have shown a positive response to somatostatin analogues treatment. The CHMP’s favorable opinion is based on results from a comprehensive clinical ...

"Oczyesa has the potential to advance the standard of care for patients living with acromegaly by enhancing octreotide plasma exposure and enabling easy and convenient once-monthly self-administration ...